Dublin, Ireland, 17th October 2016 – ICON plc, (NASDAQ: ICLR) a global provider of drug development solutions and services to the pharmaceutical, biotechnology and medical device industries, today announced that it has been awarded Contract Services Company of the Year at the annual Pharma Industry Awards, which took place in Dublin on October 13th.
The Pharma Industry Awards is the premier awards ceremony for recognising and celebrating the most original and innovative individuals and companies that demonstrate excellence in the Irish Pharma sector. ICON received three nominations for the 2016 awards:
Commenting on the award, ICON’s Chief Operating Officer, Dr. Steve Cutler, said “We are delighted to be honoured as the industry’s best contract services company for 2016. Over the past year we have continued to work hard to provide our clients with the best solutions and expertise to help them develop their products more efficiently and also drive their commercial success. It is very pleasing to see the efforts of our employees being rewarded.”
Full details of the Pharma Industry Awards can be viewed at http://pharmaawards.ie/
About ICON plc
ICON plc is a global provider of drug development solutions and services to the pharmaceutical, biotechnology and medical device industries. The company specialises in the strategic development, management and analysis of programs that support clinical development - from compound selection to Phase I-IV clinical studies. With headquarters in Dublin, Ireland, ICON currently, operates from 89 locations in 37 countries and has approximately 12,300 employees.
Further information is available at www.iconplc.com
ICON Media Contact
+44 (0) 207 067 0272
This press release contains forward-looking statements. These statements are based on management's current expectations and information currently available, including current economic and industry conditions. These statements are not guarantees of future performance or actual results, and actual results, developments and business decisions may differ from those stated in this press release. The forward-looking statements are subject to future events, risks, uncertainties and other factors that could cause actual results to differ materially from those projected in the statements, including, but not limited to, the ability to enter into new contracts, maintain client relationships, manage the opening of new offices and offering of new services, the integration of new business mergers and acquisitions, as well as economic and global market conditions and other risks and uncertainties detailed from time to time in SEC reports filed by ICON, all of which are difficult to predict and some of which are beyond our control. For these reasons, you should not place undue reliance on these forward-looking statements when making investment decisions. The word "expected" and variations of such words and similar expressions are intended to identify forward-looking statements. Forward-looking statements are only as of the date they are made and we do not undertake any obligation to update publicly any forward-looking statement, either as a result of new information, future events or otherwise. More information about the risks and uncertainties relating to these forward-looking statements may be found in SEC reports filed by ICON, including its Form 20-F, F-1, S-8 and F-3, which are available on the SEC's website at http://www.sec.gov.